{"uri": "eng-9419923", "concepts": [{"uri": "http://en.wikipedia.org/wiki/Natural_killer_cell", "type": "wiki", "score": 100, "label": {"eng": "Natural killer cell"}}, {"uri": "http://en.wikipedia.org/wiki/Autoimmune_disease", "type": "wiki", "score": 79, "label": {"eng": "Autoimmune disease"}}, {"uri": "http://en.wikipedia.org/wiki/Interleukin_15", "type": "wiki", "score": 66, "label": {"eng": "Interleukin 15"}}, {"uri": "http://en.wikipedia.org/wiki/Acute_myeloid_leukemia", "type": "wiki", "score": 66, "label": {"eng": "Acute myeloid leukemia"}}, {"uri": "http://en.wikipedia.org/wiki/Lupus_nephritis", "type": "wiki", "score": 62, "label": {"eng": "Lupus nephritis"}}, {"uri": "http://en.wikipedia.org/wiki/Allotransplantation", "type": "wiki", "score": 62, "label": {"eng": "Allotransplantation"}}, {"uri": "http://en.wikipedia.org/wiki/Cell_therapy", "type": "wiki", "score": 56, "label": {"eng": "Cell therapy"}}, {"uri": "http://en.wikipedia.org/wiki/Cryopreservation", "type": "wiki", "score": 56, "label": {"eng": "Cryopreservation"}}, {"uri": "http://en.wikipedia.org/wiki/B_cell", "type": "wiki", "score": 53, "label": {"eng": "B cell"}}, {"uri": "http://en.wikipedia.org/wiki/Chief_executive_officer", "type": "wiki", "score": 46, "label": {"eng": "Chief executive officer"}}, {"uri": "http://en.wikipedia.org/wiki/Biopharmaceutical", "type": "wiki", "score": 45, "label": {"eng": "Biopharmaceutical"}}, {"uri": "http://en.wikipedia.org/wiki/Blood", "type": "wiki", "score": 44, "label": {"eng": "Blood"}}, {"uri": "http://en.wikipedia.org/wiki/CAR_T_cell", "type": "wiki", "score": 42, "label": {"eng": "CAR T cell"}}, {"uri": "http://en.wikipedia.org/wiki/Clinical_trial", "type": "wiki", "score": 42, "label": {"eng": "Clinical trial"}}, {"uri": "http://en.wikipedia.org/wiki/NKG2D", "type": "wiki", "score": 40, "label": {"eng": "NKG2D"}}, {"uri": "http://en.wikipedia.org/wiki/Ligand", "type": "wiki", "score": 40, "label": {"eng": "Ligand"}}, {"uri": "http://en.wikipedia.org/wiki/Cytokine", "type": "wiki", "score": 40, "label": {"eng": "Cytokine"}}, {"uri": "http://en.wikipedia.org/wiki/Cell_membrane", "type": "wiki", "score": 40, "label": {"eng": "Cell membrane"}}, {"uri": "http://en.wikipedia.org/wiki/Disease", "type": "wiki", "score": 40, "label": {"eng": "Disease"}}, {"uri": "http://en.wikipedia.org/wiki/Biotechnology", "type": "wiki", "score": 39, "label": {"eng": "Biotechnology"}}, {"uri": "http://en.wikipedia.org/wiki/San_Francisco", "type": "loc", "score": 32, "label": {"eng": "San Francisco"}, "location": {"type": "place", "label": {"eng": "San Francisco"}, "country": {"type": "country", "label": {"eng": "United States"}}}}], "eventDate": "2024-03-21", "totalArticleCount": 7, "title": {"eng": "Nkarta Inc (NKTX) Posts Full Year 2023 Financial Results: A Focus on NKX019 and Pipeline Realignment"}, "summary": {"eng": "On March 21, 2024, Nkarta Inc (NASDAQ:NKTX), a clinical-stage biopharmaceutical company focused on engineered natural killer (NK) cell therapies for cancer treatment, released its 8-K filing, detailing financial results for the fourth quarter and the full year ended December 31, 2023. The company, based in South San Francisco, California, is known for leveraging NK cells to identify and kill abnormal cells and recruit adaptive immune effectors for durable responses in cancer treatment.\n\nFinancial"}, "location": {"type": "place", "label": {"eng": "San Francisco"}, "country": {"type": "country", "label": {"eng": "United States"}}}, "categories": [{"uri": "dmoz/Health/Conditions_and_Diseases/Cancer", "label": "dmoz/Health/Conditions and Diseases/Cancer", "wgt": 74}, {"uri": "dmoz/Science/Biology/Cell_Biology", "label": "dmoz/Science/Biology/Cell Biology", "wgt": 50}, {"uri": "dmoz/Business/Energy/Fuel_Cells", "label": "dmoz/Business/Energy/Fuel Cells", "wgt": 61}, {"uri": "news/Business", "label": "news/Business", "wgt": 86}], "articleCounts": {"eng": 7}, "sentiment": 0.1529411764705881, "wgt": 448675200, "relevance": 1}